210 related articles for article (PubMed ID: 23590467)
1. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.
Yip-Schneider MT; Wu H; Stantz K; Agaram N; Crooks PA; Schmidt CM
BMC Cancer; 2013 Apr; 13():194. PubMed ID: 23590467
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Yip-Schneider MT; Wu H; Hruban RH; Lowy AM; Crooks PA; Schmidt CM
Pancreas; 2013 Jan; 42(1):160-7. PubMed ID: 22699205
[TBL] [Abstract][Full Text] [Related]
3. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
4. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Knoop RF; Sparn M; Waldmann J; Plassmeier L; Bartsch DK; Lauth M; Hudemann C; Fendrich V
Neoplasia; 2014 Jun; 16(6):463-70. PubMed ID: 24953430
[TBL] [Abstract][Full Text] [Related]
5. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
6. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
7. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
8. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
Husain K; Centeno BA; Chen DT; Hingorani SR; Sebti SM; Malafa MP
Cancer Prev Res (Phila); 2013 Oct; 6(10):1074-83. PubMed ID: 23963802
[TBL] [Abstract][Full Text] [Related]
9. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
Husain K; Francois RA; Yamauchi T; Perez M; Sebti SM; Malafa MP
Mol Cancer Ther; 2011 Dec; 10(12):2363-72. PubMed ID: 21971120
[TBL] [Abstract][Full Text] [Related]
11. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
12. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
13. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
Müerköster S; Arlt A; Witt M; Gehrz A; Haye S; March C; Grohmann F; Wegehenkel K; Kalthoff H; Fölsch UR; Schäfer H
Int J Cancer; 2003 Apr; 104(4):469-76. PubMed ID: 12584745
[TBL] [Abstract][Full Text] [Related]
14. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
15. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
Zhuang Z; Ju HQ; Aguilar M; Gocho T; Li H; Iida T; Lee H; Fan X; Zhou H; Ling J; Li Z; Fu J; Wu M; Li M; Melisi D; Iwakura Y; Xu K; Fleming JB; Chiao PJ
Clin Cancer Res; 2016 Mar; 22(6):1432-44. PubMed ID: 26500238
[TBL] [Abstract][Full Text] [Related]
16. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
Mamaghani S; Patel S; Hedley DW
BMC Cancer; 2009 Apr; 9():132. PubMed ID: 19405981
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
19. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
